Friday, February 2, 2018


ATRA Atara Biotherapeutics, Inc. gains 88% Feb 2, 2018

Atara Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of muscle wasting conditions and oncology. Its lead product candidate is PINTA 745, which is in a Phase II clinical trial for the treatment of protein-energy wasting in end-stage renal disease patients. The company is also developing STM 434, a targeted therapy for ovarian cancer and other solid tumors; and a pipeline of product candidates that are in preclinical development. Atara Biotherapeutics, Inc. was founded in 2012 and is headquartered in Brisbane, California.

Subscribe by Email

Follow Updates Articles from This Blog via Email

No Comments

TradeVisor Product Review

Review I II III IV

Blog Archive